Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
65
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Letter to Editor “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs”: Important concerns on the validity of this article.

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We thank the new editor-in-chief of Food and Chemical Toxicology (FCT) journal for giving us the opportunity to present our contradictions to readers and to the scientific community about the review by Seneff et al. titled “Innate immunosuppression by SARS-CoV-2 mRNA vaccinations: the role of G quadruplexes, exosomes and microRNAs” (1). The Seneff et al. paper is still available without any note of editorial concern and has been widely read, propagated, and cited despite several gross errors observed. Public health consequences of publishing claims like “billions of lives are potentially at risk” with COVID-19 mRNA vaccines in a renowned scientific journal are not anecdotal, especially when the article is widely disseminated among general public. It is indeed the second most shared paper of the journal according to Altmetric data, with an attention score of 18541, 2nd/4980 outputs from the FCT Journal in 2022. With such high metrics, we could expect a paradigm-breaker article. In details, the authors claim that mRNA COVID-19 vaccines are responsible for the “suppression of type I interferon responses” resulting “in impaired innate immunity” and therefore that they “potentially cause increased risk to infectious diseases and cancer”. Such strong claims probably explain the public attention raised by this article, but these assertions are not supported by the cited literature, the suggested mechanisms rely on a cascade of improbable and unsupported hypotheses. In Table 1 , we present a non-exhaustive list of major misunderstandings of the literature cited in this Letter. The authors rely on hypothetical physiological disturbances induced by Covid-19 vaccination. For example, they suggest a possible increased risk of occurrence for various cancers which has not been published so far (2); in contrast, vaccination is still highly recommended for patients with cancer (3). No causal relationship can be established between the biological mechanisms described by the authors and the alleged effects of mRNA vaccines. Some claims came from the erroneous interpretations of the Vaccine Adverse Events Database (VAERS). The misuse of this database has extensively been described (4, 5, 6). In addition, the analysis proposed by the authors only takes into account the relative values of the occurrences of descriptive adverse events for SARS-COV-2 or non–SARS-COV-2 vaccines without taking into account either the number of injections for each vaccine or the differences in the accuracy of the pharmacovigilance. Thus, no conclusion can be drawn from this analysis. To date, no analysis of the data from the VAERS database supporting the hypothesis of a significant increased mortality secondary to vaccination is available (7,8). Anti-SARS-CoV-2 vaccination still has a very favorable risk-benefit ratio, saved and will save lives (9, 10, 11, 12). Table 1 Summary of some bibliography misunderstandings Table 1 Ref Quote Misunderstandings Liu et al., 2021 "Vaccination has also been demonstrated to suppress both IRF7 and STAT2" This reference only focuses on one non-mRNA vaccine (inactivated SARS-CoV-2 Vaccine (Vero Cell)) and is thus irrelevant to the authors' focus on mRNA vaccines. Goldman et al., 2021 “The case study described earlier in this paper strongly supports the hypothesis that these injections induce accelerated lymphoma progression in follicular B-cells” A causal link cannot be established based on a single case study as referred to in the quoted article (which reports a case of post-vaccine T angio-immunoblastic lymphoma and not B- follicular NHL). No increase of vaccine induced lymphomas have been reported so far. Anti-SARS-CoV-2 vaccines, on the contrary, are known to be weakly immunogenic in patients with lymphoid hemopathy, especially if they are treated with anti-CD20 monoclonal antibodies (13) Karikó et al., 2005) "Human cells recognize viral RNA as foreign, and this leads to upregulation of type I IFNs" Reference is not specific to viral RNA but describes an upregulation that occurs with “a variety of natural RNAs”. The paper is dedicated to the hypothesis “that nucleoside modification suppresses the immune-stimulatory effect of RNA” thus giving evidence that could reduce the concerns of the authors when designing future mRNA vaccines. Actually, this paper opposes the author’s hypothesis since mRNA vaccines have been designed with pseudo-uridines on purpose. Forni and Mantovani, 2021 As the authors declared: "Due to the short development time and the novelty of the technologies adopted, these vaccines will be deployed with several unresolved issues that only the passage of time will permit to clarify" The reference mainly emphasizes that "Technical problems connected with the production of billions of doses and ethical ones connected with the availability of these vaccines also in the poorest countries, are imminent challenges facing us. It is our tenet that in the long run more than one vaccine will be needed to ensure equitable global access, protection of diverse subjects and immunity against viral variants." In this context, the pledges put forward both by pharmaceutical companies and the director of the US Objective Warp Speed (14) to keep rigorous efficacy and safety standards as an absolutely central issue in COVID-19 vaccine development are reassuring. By not telling which “unresolved issues” are meant in this paper, the reader might be misled by the author’s out of context quotation. Vanderlugt and Miller, 2002 "These cytokines can induce autoantibody production through epitope spreading" The reference is focused on autoimmune and virus-induced immunity with no mention to post-vaccination autoimmunity and is thus irrelevant in the authors’ assumptions context.«Understanding the cellular and molecular basis of epitope spreading in various chronic immune-mediated human diseases [….] is crucial to understanding the pathogenesis of these diseases» clearly does not refer to mRNA vaccines. Simone et al.,2021 "COVID-19 vaccines cause myocarditis and pericarditis, with an increased risk in particular for men below the age of 50" No information about pericarditis in the provided reference which is therefore irrelevant to support the authors’ claim. “We evaluated acute myocarditis incidence and clinical outcomes among adults following mRNA vaccination in an integrated health care system in the US.” Jain et al., 2021 "COVID-19 vaccines cause myocarditis and pericarditis, with an increased risk in particular for men below the age of 50" The study was not intended to identify and/or track pericarditis and was focused on the clinical and imaging characteristics of coronavirus disease 2019 vaccination–associated myocarditis. “In this study, we aimed to characterize the clinical presentation, short-term prognosis, and myocardial tissue changes as noted on CMR or cardiac MRI in pediatric patients with coronavirus disease 2019 vaccination-associated myocarditis.» Choi S et al, 2021Verma et al., 2021 "Fatal cases of COVID-19 vaccination have been described" Two case reports of death occurring 5 days and 14 days after the first and the second dose of mRNA vaccine.Choi S. et al. conclude that “The primary cause of death was determined to be myocarditis, causally-associated with the BNT162b2 vaccine».Verma et al. mention that "a direct causal relationship cannot be definitively established."Thus, no general conclusions can be drawn from these two cases.No published data support the hypothesis that SARS-CoV-2 vaccines could be a significant cause of fatal issues. Wei et al. “Also, under conditions of overwhelming production of SARS-CoV-2 spike glycoprotein due to SARS-CoV-2 molecular vaccination, it would of course be expected that a significant proportion of over-abundant intracellular spike glycoproteins would also be exported via exosome cargoes” The paper mentions that “exosomes bear specific repertoires of proteins and RNAs, indicating the existence of mechanisms that control the sorting of molecules into them” which contradicts the author’s claim. No reference “Since these vaccines are specifically designed to induce high and ongoing production of SARS-CoV-2 spike glycoproteins, the implications are ominous.” In a study on 13 healthy volunteers, S1 antigen was detected as early as day 1 postvaccination, and peak levels were detected on average 5 days after the first injection, with no S1 antigen detected at day 10 (15). Spike protein was detectable in 3 of 13 participants an average of 15 days after the first injection. After the second vaccine dose, no S1 or spike antigen was detectable, and both antigens remained undetectable through day 56.Therefore, the assumption by Seneff et al. is wrong. Our collective is not against scientific debate and controversy. Strong claims require strong evidence, especially when published in a journal with such a high impact factor. Fortunately, to our knowledge, no publication has reported an increased risk of cancer after COVID-19 mRNA vaccination. Furthermore, these vaccines are still highly recommended for patients with active cancer undergoing treatment without any particular contraindications. Seneff et al.’s paper resembles a pre-established hypotheses with cherry-picked cell line dependent mechanisms that do not occur in a real-life setting. It is not supported by actual and strong data. Actually, it lacks the scientific rigor required in such a context and leads to science denial with all the bad consequences associated with vaccine hesitancy. We therefore strongly recommend that the new editor to retracts this paper and put an end to the harm caused to public health, getting back to a sane scientific debate where sufficient evidence is required to publish ground-breaking scientific papers. Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

          Background Following the emergency use authorisation of the Pfizer–BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Health (MoH) launched a campaign to immunise the 6·5 million residents of Israel aged 16 years and older. We estimated the real-world effectiveness of two doses of BNT162b2 against a range of SARS-CoV-2 outcomes and to evaluate the nationwide public-health impact following the widespread introduction of the vaccine. Methods We used national surveillance data from the first 4 months of the nationwide vaccination campaign to ascertain incident cases of laboratory-confirmed SARS-CoV-2 infections and outcomes, as well as vaccine uptake in residents of Israel aged 16 years and older. Vaccine effectiveness against SARS-CoV-2 outcomes (asymptomatic infection, symptomatic infection, and COVID-19-related hospitalisation, severe or critical hospitalisation, and death) was calculated on the basis of incidence rates in fully vaccinated individuals (defined as those for whom 7 days had passed since receiving the second dose of vaccine) compared with rates in unvaccinated individuals (who had not received any doses of the vaccine), with use of a negative binomial regression model adjusted for age group (16–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and ≥85 years), sex, and calendar week. The proportion of spike gene target failures on PCR test among a nationwide convenience-sample of SARS-CoV-2-positive specimens was used to estimate the prevelance of the B.1.1.7 variant. Findings During the analysis period (Jan 24 to April 3, 2021), there were 232 268 SARS-CoV-2 infections, 7694 COVID-19 hospitalisations, 4481 severe or critical COVID-19 hospitalisations, and 1113 COVID-19 deaths in people aged 16 years or older. By April 3, 2021, 4 714 932 (72·1%) of 6 538 911 people aged 16 years and older were fully vaccinated with two doses of BNT162b2. Adjusted estimates of vaccine effectiveness at 7 days or longer after the second dose were 95·3% (95% CI 94·9–95·7; incidence rate 91·5 per 100 000 person-days in unvaccinated vs 3·1 per 100 000 person-days in fully vaccinated individuals) against SARS-CoV-2 infection, 91·5% (90·7–92·2; 40·9 vs 1·8 per 100 000 person-days) against asymptomatic SARS-CoV-2 infection, 97·0% (96·7–97·2; 32·5 vs 0·8 per 100 000 person-days) against symptomatic COVID-19, 97·2% (96·8–97·5; 4·6 vs 0·3 per 100 000 person-days) against COVID-19-related hospitalisation, 97·5% (97·1–97·8; 2·7 vs 0·2 per 100 000 person-days) against severe or critical COVID-19-related hospitalisation, and 96·7% (96·0–97·3; 0·6 vs 0·1 per 100 000 person-days) against COVID-19-related death. In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined. 8006 of 8472 samples tested showed a spike gene target failure, giving an estimated prevalence of the B.1.1.7 variant of 94·5% among SARS-CoV-2 infections. Interpretation Two doses of BNT162b2 are highly effective across all age groups (≥16 years, including older adults aged ≥85 years) in preventing symptomatic and asymptomatic SARS-CoV-2 infections and COVID-19-related hospitalisations, severe disease, and death, including those caused by the B.1.1.7 SARS-CoV-2 variant. There were marked and sustained declines in SARS-CoV-2 incidence corresponding to increasing vaccine coverage. These findings suggest that COVID-19 vaccination can help to control the pandemic. Funding None.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

            Background The first COVID-19 vaccine outside a clinical trial setting was administered on Dec 8, 2020. To ensure global vaccine equity, vaccine targets were set by the COVID-19 Vaccines Global Access (COVAX) Facility and WHO. However, due to vaccine shortfalls, these targets were not achieved by the end of 2021. We aimed to quantify the global impact of the first year of COVID-19 vaccination programmes. Methods A mathematical model of COVID-19 transmission and vaccination was separately fit to reported COVID-19 mortality and all-cause excess mortality in 185 countries and territories. The impact of COVID-19 vaccination programmes was determined by estimating the additional lives lost if no vaccines had been distributed. We also estimated the additional deaths that would have been averted had the vaccination coverage targets of 20% set by COVAX and 40% set by WHO been achieved by the end of 2021. Findings Based on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million (95% credible interval [Crl] 13·7–15·9) deaths from COVID-19 in 185 countries and territories between Dec 8, 2020, and Dec 8, 2021. This estimate rose to 19·8 million (95% Crl 19·1–20·4) deaths from COVID-19 averted when we used excess deaths as an estimate of the true extent of the pandemic, representing a global reduction of 63% in total deaths (19·8 million of 31·4 million) during the first year of COVID-19 vaccination. In COVAX Advance Market Commitment countries, we estimated that 41% of excess mortality (7·4 million [95% Crl 6·8–7·7] of 17·9 million deaths) was averted. In low-income countries, we estimated that an additional 45% (95% CrI 42–49) of deaths could have been averted had the 20% vaccination coverage target set by COVAX been met by each country, and that an additional 111% (105–118) of deaths could have been averted had the 40% target set by WHO been met by each country by the end of 2021. Interpretation COVID-19 vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact in these settings, reinforcing the need for global vaccine equity and coverage. Funding Schmidt Science Fellowship in partnership with the Rhodes Trust; WHO; UK Medical Research Council; Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation; National Institute for Health Research; and Community Jameel.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

              SARS-CoV-2 proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. 11 of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day one after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of IgG and IgA.
                Bookmark

                Author and article information

                Journal
                Food Chem Toxicol
                Food Chem Toxicol
                Food and Chemical Toxicology
                Published by Elsevier Ltd.
                0278-6915
                1873-6351
                14 June 2023
                14 June 2023
                : 113897
                Affiliations
                [1]Medical Oncology Department, Polyclinique Saint-Jean, Cagnes-sur-Mer, France
                [2]Not Affiliated, Essaouira, Morrocco
                [3]Media and Information Technology, Linköping University, Norrköping, Sweden
                [4]Not Affiliated
                [5]Biopathology department, Gustave Roussy Anticancer Canter, Villejuif, France
                [6]Not Affiliated, Strasbourg, France
                [7]Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center - Jerry H. Hodge School of Pharmacy, Amarillo, Texas, United States of America
                [8]Department of Nephrology, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
                [9]Department of Immunology & UR2CA, Côte d'Azur University, CHU Nice, 151 route Saint-Antoine de Ginestière 06200 Nice, France
                [10]Université de Bordeaux, INSERM Unité 1312, 229 cours de l'Argonne, 33076 Bordeaux, France
                Author notes
                []Corresponding author :
                Article
                S0278-6915(23)00299-5 113897
                10.1016/j.fct.2023.113897
                10265941
                37328089
                fbacc4ca-d5b9-4f3c-a018-8fd7fa0918bf
                © 2023 Published by Elsevier Ltd.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Letter to the Editor

                Toxicology
                Toxicology

                Comments

                Comment on this article